Disease · HP_0002381
Aphasia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Aphasia. Diseases, record HP_0002381. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002381
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Aphasia
- Open Targets ID
- HP_0002381
- Other names
- Difficulty finding words, Losing words, Loss of words
- Highest stage of its drugs
- Phase 3, for 1 of its 10 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DONEPEZIL | CHEMBL502 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVODOPA | CHEMBL1009 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AMANTADINE | CHEMBL660 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBIDOPA | CHEMBL1200748 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXTROAMPHETAMINE | CHEMBL612 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESCITALOPRAM | CHEMBL1508 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MEPIVACAINE | CHEMBL1087 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVETIRACETAM | CHEMBL1286 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GALANTAMINE | CHEMBL659 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VENLAFAXINE | CHEMBL637 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets26
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ACHE | Acetylcholinesterase | 2 | Acetylcholinesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/43 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 2 | Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Phase 2 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 2 | Serotonin transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 1 | https://conductscience.org/library/genes/774 | Drugs and targets |
| DDC | Aromatic-L-amino-acid decarboxylase | 1 | DOPA decarboxylase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1644 | Drugs and targets |
| DRD3 | D(3) dopamine receptor | 1 | Dopamine D3 receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/2905 | Drugs and targets |
1 to 10 of 26
See all 26 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03588572 | The Effect of Venlafaxine on Language Function in Patients With Subcortical Aphasia: A fMRI Study | Not applicable | 43 | 2019-10-03 | Subcortical Aphasia, Ischemic Stroke | VENLAFAXINE | Its record names the disease | ClinicalTrials.gov |
| NCT01429077 | Augmenting Language Therapy for Aphasia: Levodopa | Phase 2/3 | 36 | 2013-11-28 | Nonfluent Aphasia, Stroke | CARBIDOPA, LEVODOPA | Its record names the disease | ClinicalTrials.gov |
| NCT02514044 | Dextroamphetamine and tDCS to Improve the Fluency | Phase 2 | 10 | 2018-08-03 | Stroke | DEXTROAMPHETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT03843463 | Escitalopram and Language Intervention for Subacute Aphasia | Phase 2 | 88 | Aphasia, Stroke | ESCITALOPRAM | Its record names the disease | ClinicalTrials.gov | |
| NCT00227461 | Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. | Phase 1 | 50 | Aphasia, Stroke | LEVETIRACETAM | Its record names the disease | ClinicalTrials.gov | |
| NCT00821691 | Action of Amantadine on Post-Stroke Aphasic Patients | Phase 2/3 | 50 | Cerebral Infarction | AMANTADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05222828 | Effects of Mepivacaine on the Neurological Sequelae of Cerebral Infarction | Phase 2 | 38 | Ischemic Stroke | MEPIVACAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04134416 | Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia | Phase 3 | 20 | Aphasia, Stroke | DONEPEZIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00941265 | Effect of Dopaminergic Medication on Recovery of Aphasia | Not applicable | 12 | Aphasia | LEVODOPA | Its record names the disease | ClinicalTrials.gov | |
| NCT01129479 | Galantamine Treatment for Nonfluent Aphasia in Stroke Patients | Not applicable | 8 | Aphasia, Stroke | GALANTAMINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Levodopa vs Inactive Pill: serious adverse events | 0 of 19 | 0 of 14 | 33 | NCT01429077 | Trial comparisons |
| Venlafaxine Group vs Controlled Group: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT03588572 | Trial comparisons |
| Venlafaxine Group vs Controlled Group: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT03588572 | Trial comparisons |
| D-AMP+tDCS+Speech Therapy vs Placebo+tDCS+Speech Therapy: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT02514044 | Trial comparisons |
| D-AMP+tDCS+Speech Therapy vs Placebo+tDCS+Speech Therapy: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT02514044 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002381
GET https://conductscience.org/api/diseases/v1/HP_0002381/targets?page=2